Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Introduction: Parkinson's disease (PD) is among the most common of the neurodegenerative disorders. Treatment is primarily focused on correcting neurotransmitter imbalances. Several classes of medication are available for this purpose.Areas covered: A Medline search was performed to gather information about the safety of the medications approved for the treatment of the motor symptoms of PD. This was supplemented with additional articles obtained from online sources and information provided by the FDA and the manufacturers. The focus of this review is the side-effect and safety profiles of carbidopa/levodopa, dopamine agonists, selective monoamine oxidase inhibitors, catechol-o-methyltransferase inhibitors, anticholinergics and amantadine.Expert opinion: Though serious side-effects may occur, as a group, the medications used for the treatment of PD motor symptoms tend to produce side-effects that are mild to moderate in nature, and that primarily reflect the focus on dopaminergic therapies. Care plans for Parkinson's patients should be approached based on the needs of the individual as disease presentation, lifestyle, level of disability, concurrent disease states and the presence of non-motor symptoms make each case unique. Patients and caregivers must have realistic expectations about the use of PD medications.

Original languageEnglish
Pages (from-to)1055-1069
Number of pages15
JournalExpert Opinion on Drug Safety
Volume13
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Parkinson Disease
Safety
Amantadine
Catechol O-Methyltransferase
Monoamine Oxidase Inhibitors
Dopamine Agonists
Expert Testimony
Cholinergic Antagonists
Therapeutics
Neurodegenerative Diseases
Caregivers
Neurotransmitter Agents
Life Style

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease. / Faulkner, Michele A.

In: Expert Opinion on Drug Safety, Vol. 13, No. 8, 2014, p. 1055-1069.

Research output: Contribution to journalReview article

@article{91ec5799e8e14a85a816d170f2ef00cd,
title = "Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease",
abstract = "Introduction: Parkinson's disease (PD) is among the most common of the neurodegenerative disorders. Treatment is primarily focused on correcting neurotransmitter imbalances. Several classes of medication are available for this purpose.Areas covered: A Medline search was performed to gather information about the safety of the medications approved for the treatment of the motor symptoms of PD. This was supplemented with additional articles obtained from online sources and information provided by the FDA and the manufacturers. The focus of this review is the side-effect and safety profiles of carbidopa/levodopa, dopamine agonists, selective monoamine oxidase inhibitors, catechol-o-methyltransferase inhibitors, anticholinergics and amantadine.Expert opinion: Though serious side-effects may occur, as a group, the medications used for the treatment of PD motor symptoms tend to produce side-effects that are mild to moderate in nature, and that primarily reflect the focus on dopaminergic therapies. Care plans for Parkinson's patients should be approached based on the needs of the individual as disease presentation, lifestyle, level of disability, concurrent disease states and the presence of non-motor symptoms make each case unique. Patients and caregivers must have realistic expectations about the use of PD medications.",
author = "Faulkner, {Michele A.}",
year = "2014",
doi = "10.1517/14740338.2014.931369",
language = "English",
volume = "13",
pages = "1055--1069",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease

AU - Faulkner, Michele A.

PY - 2014

Y1 - 2014

N2 - Introduction: Parkinson's disease (PD) is among the most common of the neurodegenerative disorders. Treatment is primarily focused on correcting neurotransmitter imbalances. Several classes of medication are available for this purpose.Areas covered: A Medline search was performed to gather information about the safety of the medications approved for the treatment of the motor symptoms of PD. This was supplemented with additional articles obtained from online sources and information provided by the FDA and the manufacturers. The focus of this review is the side-effect and safety profiles of carbidopa/levodopa, dopamine agonists, selective monoamine oxidase inhibitors, catechol-o-methyltransferase inhibitors, anticholinergics and amantadine.Expert opinion: Though serious side-effects may occur, as a group, the medications used for the treatment of PD motor symptoms tend to produce side-effects that are mild to moderate in nature, and that primarily reflect the focus on dopaminergic therapies. Care plans for Parkinson's patients should be approached based on the needs of the individual as disease presentation, lifestyle, level of disability, concurrent disease states and the presence of non-motor symptoms make each case unique. Patients and caregivers must have realistic expectations about the use of PD medications.

AB - Introduction: Parkinson's disease (PD) is among the most common of the neurodegenerative disorders. Treatment is primarily focused on correcting neurotransmitter imbalances. Several classes of medication are available for this purpose.Areas covered: A Medline search was performed to gather information about the safety of the medications approved for the treatment of the motor symptoms of PD. This was supplemented with additional articles obtained from online sources and information provided by the FDA and the manufacturers. The focus of this review is the side-effect and safety profiles of carbidopa/levodopa, dopamine agonists, selective monoamine oxidase inhibitors, catechol-o-methyltransferase inhibitors, anticholinergics and amantadine.Expert opinion: Though serious side-effects may occur, as a group, the medications used for the treatment of PD motor symptoms tend to produce side-effects that are mild to moderate in nature, and that primarily reflect the focus on dopaminergic therapies. Care plans for Parkinson's patients should be approached based on the needs of the individual as disease presentation, lifestyle, level of disability, concurrent disease states and the presence of non-motor symptoms make each case unique. Patients and caregivers must have realistic expectations about the use of PD medications.

UR - http://www.scopus.com/inward/record.url?scp=84904504734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904504734&partnerID=8YFLogxK

U2 - 10.1517/14740338.2014.931369

DO - 10.1517/14740338.2014.931369

M3 - Review article

VL - 13

SP - 1055

EP - 1069

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 8

ER -